Skip to content

Study · Animal study (in vivo) · horse · 1994

7 results

Effect of various doses of a gonadotropin-releasing hormone analogue on induction of ovulation in anestrous mares.

Mumford EL, Squires EL, Peterson KD, Nett TM, Jasko DJ

Journal of animal science1 Jan 1994Cited by 23 (Europe PMC)

PMID8138487 (opens in a new tab)DOI10.2527/1994.721178x (opens in a new tab)PepBankPUB-08138487
Publisher pagePubMedAsk about this study
Jump to 7 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

7 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In anestrous mares, more ovulated with 3.6-mg goserelin implants than placebo (7 versus 0, P < .05).

    In plain wordsIn mares, more ovulated with 3.6-mg goserelin implants than placebo.

    Peptide
    Goserelin
    Outcome
    IncreaseOvulation with 3.6 mg versus placebo
    Study

    horsen: not reported in source

    Anestrous mares
    Comparator
    Placebo implant
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    3.6 mg · subcutaneous implantAs given in this study (horse).

    Source sentences

    Summary
    More mares (P < .05) ovulated when given 3.6- (n = 7) or 5.4-mg (n = 6) implants than when given .9-mg implants (n = 0) or placebo (n = 0).
    1 context sentence
    Summary · context
    One hundred anestrous mares (early February) were injected s.c. with implants containing 0, .9, 1.8, 3.6, or 5.4 mg of a GnRH analogue (goserelin acetate) in an attempt to induce ovarian cyclicity.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In anestrous mares, more ovulated with 3.6-mg than .9-mg goserelin implants (7 versus 0, P < .05).

    In plain wordsIn mares, more ovulated with 3.6-mg than .9-mg goserelin implants.

    Peptide
    Goserelin
    Outcome
    IncreaseOvulation with 3.6 mg versus .9 mg
    Study

    horsen: not reported in source

    Anestrous mares
    Comparator
    Goserelin .9 mg implant
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    3.6 mg · subcutaneous implantAs given in this study (horse).

    Source sentences

    Summary
    More mares (P < .05) ovulated when given 3.6- (n = 7) or 5.4-mg (n = 6) implants than when given .9-mg implants (n = 0) or placebo (n = 0).
    1 context sentence
    Summary · context
    One hundred anestrous mares (early February) were injected s.c. with implants containing 0, .9, 1.8, 3.6, or 5.4 mg of a GnRH analogue (goserelin acetate) in an attempt to induce ovarian cyclicity.
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In anestrous mares, more ovulated with 5.4-mg goserelin implants than placebo (6 versus 0, P < .05).

    In plain wordsIn mares, more ovulated with 5.4-mg goserelin implants than placebo.

    Peptide
    Goserelin
    Outcome
    IncreaseOvulation with 5.4 mg versus placebo
    Study

    horsen: not reported in source

    Anestrous mares
    Comparator
    Placebo implant
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    5.4 mg · subcutaneous implantAs given in this study (horse).

    Source sentences

    Summary
    More mares (P < .05) ovulated when given 3.6- (n = 7) or 5.4-mg (n = 6) implants than when given .9-mg implants (n = 0) or placebo (n = 0).
    1 context sentence
    Summary · context
    One hundred anestrous mares (early February) were injected s.c. with implants containing 0, .9, 1.8, 3.6, or 5.4 mg of a GnRH analogue (goserelin acetate) in an attempt to induce ovarian cyclicity.
  4. 04AnimalAnimal study (in vivo)Efficacy outcome

    In anestrous mares, more ovulated with 5.4-mg than .9-mg goserelin implants (6 versus 0, P < .05).

    In plain wordsIn mares, more ovulated with 5.4-mg than .9-mg goserelin implants.

    Peptide
    Goserelin
    Outcome
    IncreaseOvulation with 5.4 mg versus .9 mg
    Study

    horsen: not reported in source

    Anestrous mares
    Comparator
    Goserelin .9 mg implant
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    5.4 mg · subcutaneous implantAs given in this study (horse).

    Source sentences

    Summary
    More mares (P < .05) ovulated when given 3.6- (n = 7) or 5.4-mg (n = 6) implants than when given .9-mg implants (n = 0) or placebo (n = 0).
    1 context sentence
    Summary · context
    One hundred anestrous mares (early February) were injected s.c. with implants containing 0, .9, 1.8, 3.6, or 5.4 mg of a GnRH analogue (goserelin acetate) in an attempt to induce ovarian cyclicity.
  5. 05AnimalAnimal study (in vivo)Mechanism

    In anestrous mares, LH area under the curve was greater with larger goserelin doses.

    In plain wordsIn mares, LH area under the curve was greater with larger goserelin doses.

    Peptide
    Goserelin
    Outcome
    IncreaseLH area under curve by dose
    Study

    horsen: not reported in source

    Anestrous mares
    Comparator
    Lower doses
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    .9, 1.8, 3.6, or 5.4 mg · subcutaneous implantAs given in this study (horse).

    Source sentences

    Summary
    Area under the curve (AUC) for LH was greater for mares receiving larger doses of GnRH.
    1 context sentence
    Summary · context
    One hundred anestrous mares (early February) were injected s.c. with implants containing 0, .9, 1.8, 3.6, or 5.4 mg of a GnRH analogue (goserelin acetate) in an attempt to induce ovarian cyclicity.
  6. 06AnimalAnimal study (in vivo)Mechanism

    In goserelin-treated anestrous mares, LH area under the curve was similar between ovulating and nonovulating mares.

    In plain wordsIn goserelin-treated mares, LH area under the curve was similar between ovulating and nonovulating mares.

    Peptide
    Goserelin
    Outcome
    No significant changeLH area under curve by ovulation status
    Study

    horsen: not reported in source

    Anestrous mares
    Comparator
    Nonovulating mares
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    Dose not stated · subcutaneous implantAs given in this study (horse).

    Source sentences

    Summary
    The AUC and peak LH were similar between ovulating and nonovulating mares.
    1 context sentence
    Summary · context
    One hundred anestrous mares (early February) were injected s.c. with implants containing 0, .9, 1.8, 3.6, or 5.4 mg of a GnRH analogue (goserelin acetate) in an attempt to induce ovarian cyclicity.
  7. 07AnimalAnimal study (in vivo)Mechanism

    In goserelin-treated anestrous mares, peak LH was similar between ovulating and nonovulating mares.

    In plain wordsIn goserelin-treated mares, peak LH was similar between ovulating and nonovulating mares.

    Peptide
    Goserelin
    Outcome
    No significant changePeak LH by ovulation status
    Study

    horsen: not reported in source

    Anestrous mares
    Comparator
    Nonovulating mares
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    Dose not stated · subcutaneous implantAs given in this study (horse).

    Source sentences

    Summary
    The AUC and peak LH were similar between ovulating and nonovulating mares.
    1 context sentence
    Summary · context
    One hundred anestrous mares (early February) were injected s.c. with implants containing 0, .9, 1.8, 3.6, or 5.4 mg of a GnRH analogue (goserelin acetate) in an attempt to induce ovarian cyclicity.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:35 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.